Text Size

Albiglutide Thorough ECG Study in Healthy Volunteers

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01406262
First received: July 28, 2011
Last updated: January 5, 2012
Last verified: January 2012
History of Changes
  Purpose

This study is designed to investigate the effect of treatment with albiglutide on the cardiac repolarization (corrected QT interval) in healthy male and female subjects. Moxifloxacin, a positive control, or moxifloxacin placebo will be given in order to validate the ability of the study to detect a change in the corrected QT interval.


Condition Intervention Phase
Healthy Subjects
 Biological: Albiglutide
Drug: Moxifloxacin
 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Basic Science
Official Title: A Randomized, Double-blind, Parallel, Nested Crossover Study to Investigate the Effect of Albiglutide on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Male and Female Subjects: A Thorough ECG Study Employing Placebo, Albiglutide, and a Positive Control (Moxifloxacin)

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • QTc interval [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
    Measurement of cardiac repolarization after albiglutide dosing


Secondary Outcome Measures:
  • QTc interval [ Time Frame: Day 4 ] [ Designated as safety issue: No ]
    Measurement of cardiac repolarization after albiglutide dosing

  • QT interval [ Time Frame: Day -1 and Day 40 ] [ Designated as safety issue: No ]
    Determination of the effect of moxifloxacin on cardiac repolarization

  • Number of participants with adverse events [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
    Number of participants with adverse events


Enrollment: 94
Study Start Date: July 2011
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Albiglutide + moxifloxacin placebo
Once weekly subcutaneous injection of albiglutide for 6 weeks plus oral tablet of moxifloxacin matching placebo on Days -1 and 40
 Biological: Albiglutide
once weekly subcutaneous injection
Active Comparator: Albiglutide matching placebo + moxifloxacin
Once weekly subcutaneous injection of albiglutide matching placebo for 6 weeks, given with oral 400mg moxifloxacin tablet on Day -1 and moxifloxacin matching placebo on Day 40, or weekly albiglutide matching placebo for 6 weeks plus oral moxifloxacin matching placebo on Day -1 then oral 400mg moxifloxacin on Day 40
 Drug: Moxifloxacin
oral tablet

Detailed Description:

This is a Phase I, randomized, double-blind study designed to investigate the effect of treatment with albiglutide given weekly over 6 weeks on the cardiac repolarization (corrected QT interval) in healthy male and female subjects. Moxifloxacin, a positive control, or moxifloxacin placebo will be given in order to validate the ability of the study to detect a change in the corrected QT interval.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male or nonpregnant, nonlactating female
  • Subject considered to be in good health as judged by the absence of clinically significant diseases or clinically significant abnormal laboratory values
  • BMI is ≥18 kg/m2 and ≤30 kg/m2
  • Nonsmoker

Exclusion Criteria:

  • Positive test results for hepatitis B, hepatitis C, or human immunodeficiency virus
  • History of arrythmia or use of antiarrhythmic agents
  • History of any anaphylactic reaction to any drug
  • History of significant cardiovascular or pulmonary dysfunction
  • Current or chronic history of liver disease , renal disease, CNS disorders, thyroid dysfunction, rheumatoid arthritis
  • History of alcohol or substance abuse
  • History of GI surgery that could influence gastric emptying
  • Female and using oral contraception (combined or progestogen only), implants or levonorgestrel, or injectable progesterone, or hormone replacement therapy
  • History of pancreatitis
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01406262

Locations
United States, Texas
GSK Investigational Site
Austin, Texas, United States, 78744
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: Cheri Hudson; Clinical Disclosure Advisor, GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01406262     History of Changes
Other Study ID Numbers: 107085
Study First Received: July 28, 2011
Last Updated: January 5, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
albiglutide
QT interval
cardiac repolarization
ECG study

Additional relevant MeSH terms:
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Contraceptives, Oral, Combined
 Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 16, 2013